A Study in Participants With Obesity or Overweight With at Least One Weight-related Comorbidity

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

262

Participants

Timeline

Start Date

October 1, 2024

Primary Completion Date

August 8, 2025

Study Completion Date

December 8, 2025

Conditions
Obesity or Overweight
Interventions
DRUG

AZD6234

IMP injected subcutaneously, once a week. Unit dose strength as per CSP

DRUG

Placebo comparator

Placebo matching IMP dose injected subcutaneously, once a week.

Trial Locations (41)

2035

Research Site, Maroubra

2291

Research Site, Merewether

3081

Research Site, Heidelberg

4556

Research Site, Maroochydore

21093

Research Site, Lutherville-Timonium

28625

Research Site, Statesville

29405

Research Site, North Charleston

30189

Research Site, Woodstock

32825

Research Site, Orlando

33012

Research Site, Hialeah

33606

Research Site, Tampa

33777

Research Site, Largo

36608

Research Site, Mobile

37938

Research Site, Knoxville

39157

Research Site, Ridgeland

39503

Research Site, Gulfport

46260

Research Site, Indianapolis

64111

Research Site, Kansas City

68134

Research Site, Omaha

75230

Research Site, Dallas

77642

Research Site, Port Arthur

78231

Research Site, San Antonio

78249

Research Site, San Antonio

78731

Research Site, Austin

85044

Research Site, Phoenix

90815

Research Site, Long Beach

03801

Research Site, Portsmouth

L8L 5G8

Research Site, Hamilton

N7T 4X3

Research Site, Sarnia

L4A1H2

Research Site, Stouffville

M3J 0K2

Research Site, Toronto

H4N 2W2

Research Site, Montreal

J1L 0H8

Research Site, Sherbrooke

103-0027

Research Site, Chūōku

104-0031

Research Site, Chūōku

160-0008

Research Site, Shinjuku-ku

565-0853

Research Site, Suita-shi

HU3 2PA

Research Site, Hull

Le5 4PW

Research Site, Leicester

CF64 2XX

Research Site, Penarth

S65 1DA

Research Site, Rotherham

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY